Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ConvaTec ( (GB:CTEC) ) has provided an update.
Convatec has announced its total voting rights as of October 31, 2025, with an issued share capital of 2,049,789,559 ordinary shares, of which 52,991,686 are held in treasury and not considered for dividends or voting. The total number of voting rights is 1,996,797,873, a figure crucial for shareholders under the FCA’s Disclosure and Transparency Rules. Additionally, 10,466,657 shares are in the process of settlement following a share buyback program initiated in August 2025, which will also be held in treasury once settled.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £273.00 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec is a global medical products and technologies company specializing in solutions for managing chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, operating in around 90 countries. The company is part of the FTSE 100 Index and reported revenues of over $2 billion in 2024.
Average Trading Volume: 7,400,390
Technical Sentiment Signal: Strong Buy
Current Market Cap: £4.84B
See more insights into CTEC stock on TipRanks’ Stock Analysis page.